주식/증권 ➡️ 중립

Lilly’s revenue soars 48%, driven by demand of its GLP-1s

MarketWatch - Top Stories 2026/08/05 11:17:00 7회

요약

Lilly’s sales were driven by higher-than-expected demand for Mounjaro and Zepbound, its GLP-1 drugs for Type 2 diabetes and weight loss.

원문 기사 보기

관련 뉴스

3 Ultra-High-Yield Dividend Stocks to Buy in August (1 Yields Over 13.5%)

Berkshire Hathaway Q2 operating earnings +16% Y/Y, cash at $365.5B

Cloud capex forecast calls for 29% jump in 2027 as compute demand exceeds capacity: MS

How can we minimize taxes in retirement with a $2.3 million nest egg — while buying homes in Florida and New England?

뉴스 목록으로